Fenofibric acid
Fenofibric Acid, Fibricor (fenofibric acid) is a small molecule pharmaceutical. Fenofibric acid was first approved as Fibricor on 2009-08-14. It is used to treat coronary artery disease, hypercholesterolemia, hyperlipoproteinemias, and hypertriglyceridemia in the USA. It is known to target peroxisome proliferator-activated receptor alpha, chloride channel protein 1, and fatty acid-binding protein, liver.
Download report
Favorite
Commercial
Trade Name
FDA
EMA
No data
Drug Products
FDA
EMA
New Drug Application (NDA)
New Drug Application (NDA)
Abbreviated New Drug Application (ANDA)
Abbreviated New Drug Application (ANDA)
Fenofibric acid
Tradename | Company | Number | Date | Products |
---|---|---|---|---|
FIBRICOR | Athena Neurosciences | N-022418 DISCN | 2009-08-14 | 2 products, RLD |
Hide discontinued
Labels
FDA
EMA
Brand Name | Status | Last Update |
---|---|---|
fenofibrate | ANDA | 2023-05-26 |
fenofibric acid | ANDA | 2023-05-18 |
fibricor | New Drug Application | 2020-12-29 |
Indications
FDA
EMA
Indication | Ontology | MeSH | ICD-10 |
---|---|---|---|
coronary artery disease | — | D003324 | I25.1 |
hypercholesterolemia | HP_0003124 | D006937 | — |
hyperlipoproteinemias | — | D006951 | — |
hypertriglyceridemia | EFO_0004211 | D015228 | — |
Agency Specific
FDA
EMA
No data
ATC Codes
C: Cardiovascular system drugs
— C10: Lipid modifying agents
— C10A: Lipid modifying agents, plain
— C10AB: Fibrates, lipid modifying drugs, plain
— C10AB05: Fenofibrate
— C10AB11: Choline fenofibrate
— C10B: Lipid modifying agents, combinations
— C10BA: Combinations of various lipid modifying agents
— C10BA03: Pravastatin and fenofibrate
— C10BA04: Simvastatin and fenofibrate
— C10BA09: Rosuvastatin and fenofibrate
— C10BA12: Pravastatin, ezetimibe and fenofibrate
HCPCS
No data
Clinical
Clinical Trials
18 clinical trials
View more details
Mock data
Subscribe for the real data
Subscribe for the real data
Indications Phases 4
Indication | MeSH | Ontology | ICD-10 | Ph 1 | Ph 2 | Ph 3 | Ph 4 | Other | Total |
---|---|---|---|---|---|---|---|---|---|
Hypertension | D006973 | EFO_0000537 | I10 | 1 | — | 1 | 6 | 3 | 11 |
Left ventricular hypertrophy | D017379 | EFO_0003896 | — | — | — | 1 | — | 1 |
Indications Phases 3
Indication | MeSH | Ontology | ICD-10 | Ph 1 | Ph 2 | Ph 3 | Ph 4 | Other | Total |
---|---|---|---|---|---|---|---|---|---|
Obesity | D009765 | EFO_0001073 | E66.9 | — | — | 1 | — | — | 1 |
Indications Phases 2
No data
Indications Phases 1
Indication | MeSH | Ontology | ICD-10 | Ph 1 | Ph 2 | Ph 3 | Ph 4 | Other | Total |
---|---|---|---|---|---|---|---|---|---|
Healthy volunteers/patients | — | 3 | — | — | — | 2 | 5 | ||
Food-drug interactions | D018565 | 1 | — | — | — | — | 1 |
Indications Without Phase
Indication | MeSH | Ontology | ICD-10 | Ph 1 | Ph 2 | Ph 3 | Ph 4 | Other | Total |
---|---|---|---|---|---|---|---|---|---|
Insulin resistance | D007333 | EFO_0002614 | — | — | — | — | 1 | 1 | |
Microcirculation | D008833 | — | — | — | — | 1 | 1 |
Epidemiology
Epidemiological information for investigational and approved indications
View more details
Drug
General
Drug common name | FENOFIBRIC ACID |
INN | fenofibrate |
Description | Fenofibrate is a chlorobenzophenone that is (4-chlorophenyl)(phenyl)methanone substituted by a [2-methyl-1-oxo-1-(propan-2-yloxy)propan-2-yl]oxy group at position 1 on the phenyl ring. It has a role as an antilipemic drug, an environmental contaminant, a xenobiotic and a geroprotector. It is a chlorobenzophenone, a member of monochlorobenzenes, an aromatic ether and an isopropyl ester. It is functionally related to a benzophenone. |
Classification | Small molecule |
Drug class | antihyperlipidemics (clofibrate type) |
Image (chem structure or protein) | |
Structure (InChI/SMILES or Protein Sequence) | CC(C)(Oc1ccc(C(=O)c2ccc(Cl)cc2)cc1)C(=O)O |
Target
Agency Approved
No data
Alternate
PPARA
PPARA
CLCN1
CLCN1
FABP1
FABP1
Organism
Homo sapiens
Gene name
PPARA
Gene synonyms
NR1C1, PPAR
NCBI Gene ID
Protein name
peroxisome proliferator-activated receptor alpha
Protein synonyms
Nuclear receptor subfamily 1 group C member 1, peroxisome proliferative activated receptor, alpha
Uniprot ID
Mouse ortholog
Ppara (19013)
peroxisome proliferator-activated receptor alpha (P23204)
Variants
Clinical Variant
No data
Financial
No data
Trends
PubMed Central
Top Terms for Disease or Syndrome:
Mock data
Subscribe for the real data
Subscribe for the real data
Additional graphs summarizing 12,848 documents
View more details
Safety
Black-box Warning
No Black-box warning
Adverse Events
Top Adverse Reactions
Mock data
Subscribe for the real data
Subscribe for the real data
1,867 adverse events reported
View more details
Premium feature
Learn more about premium features at pharmakb.com
Learn more